# Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial

> **NCT05639959** · — · COMPLETED · sponsor: **Saffron Pharma** · enrollment: 20 (actual)

## Conditions studied

- Acute Rhinosinusitis

## Interventions

- **DRUG:** Mometasone Nasal 50 Mcg/Inh Nasal Spray
- **DEVICE:** Nasal spray

## Key facts

- **NCT ID:** NCT05639959
- **Lead sponsor:** Saffron Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-10
- **Primary completion:** 2022-11-06
- **Final completion:** 2022-11-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639959, "Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05639959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*